Zenas BioPharma (ZBIO)
Market Price (5/8/2026): $19.19 | Market Cap: $1.0 BilSector: Health Care | Industry: Biotechnology
Zenas BioPharma (ZBIO)
Market Price (5/8/2026): $19.19Market Cap: $1.0 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -33% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 100% Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Biopharmaceutical R&D, and Targeted Therapies. | Weak multi-year price returns2Y Excs Rtn is -39%, 3Y Excs Rtn is -72% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.37, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 19% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -211 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2114% Expensive valuation multiplesP/SPrice/Sales ratio is 102x Stock price has recently run up significantly12M Rtn12 month market price return is 121% Weak revenue growthRev Chg QQuarterly Revenue Change % is null Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 263% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1723%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -2074% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 64% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -41% High stock price volatilityVol 12M is 115% Key risks[ZBIO] key risks include [1] an extreme dependence on a limited product pipeline, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -33% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 100% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Biopharmaceutical R&D, and Targeted Therapies. |
| Weak multi-year price returns2Y Excs Rtn is -39%, 3Y Excs Rtn is -72% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.37, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 19% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -211 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2114% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 102x |
| Stock price has recently run up significantly12M Rtn12 month market price return is 121% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is null |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 263% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1723%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -2074% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 64% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -41% |
| High stock price volatilityVol 12M is 115% |
| Key risks[ZBIO] key risks include [1] an extreme dependence on a limited product pipeline, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Positive Clinical Trial Results and Regulatory Progress for Lead Asset.
Zenas BioPharma announced on March 16, 2026, that its lead asset, obexelimab, met its primary and all four key secondary endpoints with high statistical significance in the Phase 3 INDIGO trial for Immunoglobulin G4-Related Disease (IgG4-RD). The company plans to submit a Biologics License Application (BLA) to the FDA in the second quarter of 2026 and a Marketing Authorization Application (MAA) to the EMA in the second half of 2026 for obexelimab in IgG4-RD.
2. Significant Insider Buying Activity.
Between January and April 2026, Zenas BioPharma saw substantial insider buying, with total insider purchases exceeding $8.77 million within the last 90 days. Notably, CEO Leon O. Moulder Jr. made repeated and aggressive purchases, including nearly $3.7 million worth of company stock in three separate transactions from January to March 2026, and an additional purchase of approximately $1.07 million for 60,000 shares in late April 2026.
Show more
Stock Movement Drivers
Fundamental Drivers
The 4.9% change in ZBIO stock from 1/31/2026 to 5/7/2026 was primarily driven by a 98.1% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 5072026 | Change |
|---|---|---|---|
| Stock Price ($) | 18.37 | 19.27 | 4.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 15 | 10 | -33.3% |
| P/S Multiple | 51.6 | 102.3 | 98.1% |
| Shares Outstanding (Mil) | 42 | 53 | -20.6% |
| Cumulative Contribution | 4.9% |
Market Drivers
1/31/2026 to 5/7/2026| Return | Correlation | |
|---|---|---|
| ZBIO | 4.9% | |
| Market (SPY) | 3.6% | 13.5% |
| Sector (XLV) | -6.1% | 33.6% |
Fundamental Drivers
The -38.3% change in ZBIO stock from 10/31/2025 to 5/7/2026 was primarily driven by a -33.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 10312025 | 5072026 | Change |
|---|---|---|---|
| Stock Price ($) | 31.25 | 19.27 | -38.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 15 | 10 | -33.3% |
| P/S Multiple | 87.2 | 102.3 | 17.3% |
| Shares Outstanding (Mil) | 42 | 53 | -21.1% |
| Cumulative Contribution | -38.3% |
Market Drivers
10/31/2025 to 5/7/2026| Return | Correlation | |
|---|---|---|
| ZBIO | -38.3% | |
| Market (SPY) | 5.5% | 3.0% |
| Sector (XLV) | 1.2% | 13.5% |
Fundamental Drivers
The 66.4% change in ZBIO stock from 4/30/2025 to 5/7/2026 was primarily driven by a 100.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302025 | 5072026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.58 | 19.27 | 66.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5 | 10 | 100.0% |
| P/S Multiple | 96.8 | 102.3 | 5.7% |
| Shares Outstanding (Mil) | 42 | 53 | -21.3% |
| Cumulative Contribution | 66.4% |
Market Drivers
4/30/2025 to 5/7/2026| Return | Correlation | |
|---|---|---|
| ZBIO | 66.4% | |
| Market (SPY) | 30.4% | 17.2% |
| Sector (XLV) | 4.9% | 23.8% |
Fundamental Drivers
nullnull
Market Drivers
4/30/2023 to 5/7/2026| Return | Correlation | |
|---|---|---|
| ZBIO | ||
| Market (SPY) | 78.7% | 20.4% |
| Sector (XLV) | 13.9% | 19.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ZBIO Return | - | - | - | -55% | 343% | -43% | 15% |
| Peers Return | 16% | 19% | 7% | -1% | 27% | 4% | 92% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 96% |
Monthly Win Rates [3] | |||||||
| ZBIO Win Rate | - | - | - | 25% | 67% | 40% | |
| Peers Win Rate | 48% | 62% | 45% | 47% | 60% | 52% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| ZBIO Max Drawdown | - | - | - | -55% | -21% | -58% | |
| Peers Max Drawdown | -7% | -9% | -19% | -16% | -14% | -6% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: AMGN, BIIB, BMY, JNJ, LLY.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/7/2026 (YTD)
How Low Can It Go
In The Past
Zenas BioPharma's stock fell 0.0% during the 2025 US Tariff Shock. Such a loss loss requires a 0.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
In The Past
Zenas BioPharma's stock fell 0.0% during the 2025 US Tariff Shock. Such a loss loss requires a 0.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Zenas BioPharma (ZBIO)
AI Analysis | Feedback
1. Zenas BioPharma is like a 'kinder, gentler' Biogen for B-cell autoimmune therapies, aiming to inhibit rather than deplete B cells.
2. Zenas BioPharma aims to be a future AbbVie for immunology franchises, starting with a novel B-cell inhibitor for multiple autoimmune conditions.
AI Analysis | Feedback
Major Product Candidate
- Obexelimab: A bifunctional monoclonal antibody in clinical development for the treatment of various autoimmune diseases, including IgG4-RD, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia.
AI Analysis | Feedback
Because Zenas BioPharma is a clinical-stage biopharmaceutical company, it has no product candidates approved for commercial sale in any country and has not generated any revenue from product sales. Therefore, Zenas BioPharma currently has no major customers.AI Analysis | Feedback
```htmlnull
```AI Analysis | Feedback
Lonnie Moulder, Chief Executive Officer and Chairman of the Board of Directors
Mr. Moulder is the Founder of Zenas BioPharma and has served as its Chief Executive Officer since August 2023, and as Chairman and a member of the board of directors since 2020. He has been the Managing Member of Tellus BioVentures, LLC, an early-stage life sciences investment fund, since March 2019. Mr. Moulder has built and sold biotech companies for a combined total exceeding $10 billion, including the sale of TESARO to GlaxoSmithKline for $5.1 billion, Abraxis BioScience to Celgene for $2.9 billion, and MGI PHARMA to Eisai for $3.9 billion. He was recognized as Entrepreneur of the Year by Ernst & Young in 2017.
Jennifer Fox, Chief Business Officer and Chief Financial Officer
Ms. Fox has served as Zenas BioPharma's Chief Business Officer and Chief Financial Officer since December 2023. She is an experienced finance and corporate development executive with over 25 years of experience in corporate finance and healthcare investment banking, during which she advised numerous private and public companies on strategy, financings, and mergers and acquisitions. Prior to joining Zenas, Ms. Fox served as Chief Financial Officer at Nuvation Bio, Inc., a publicly traded biotechnology company. Before Nuvation Bio, she was a Managing Director and Co-Head of North America Healthcare Corporate and Investment Banking Group at CitiGroup, and also held senior investment banking positions at Deutsche Bank, Bear Stearns, Bank of America, and Prudential Securities.
Joe Farmer, President and Chief Operating Officer
Mr. Farmer serves as President and Chief Operating Officer. He is an accomplished biopharma executive with approximately 25 years of transactional and operational experience across all stages of development for emerging biotechnology companies, from discovery through commercialization. Prior to Zenas, Mr. Farmer was Chief Operating Officer at Xilio Therapeutics. Before Xilio, he served as General Counsel and Corporate Secretary at TESARO, where he led global legal, compliance, and government affairs functions and was a key member of the leadership team during its acquisition by GlaxoSmithKline in 2019.
Lisa von Moltke, M.D., Head of Research and Development and Chief Medical Officer
Dr. von Moltke was appointed Head of Research and Development and Chief Medical Officer at Zenas BioPharma in March 2025, bringing over three decades of experience in drug development with expertise in autoimmune diseases. She previously served as Chief Medical Officer at Seres Therapeutics, with functional oversight of clinical development, sciences and operations, regulatory, and medical affairs. Her career includes significant leadership roles at Alkermes, Inc., where she was Senior Vice President and Head of Clinical Development, and at Sanofi/Genzyme Corporation, where she served as Vice President, Clinical and Exploratory Pharmacology. Dr. von Moltke also served as President of the American College of Clinical Pharmacology.
Haley Laken, Ph.D., Chief Scientific Officer
Dr. Laken was appointed Chief Scientific Officer of Zenas BioPharma in April 2025. She brings over two decades of leadership experience in research, development operations, scientific assessment, and strategy. Before joining Zenas, Dr. Laken served as Chief Operating Officer at Tabby Therapeutics, a privately held biotech company. She held roles of increasing responsibility at Jounce Therapeutics, culminating as Chief Development Officer, and served in a senior program leadership role at TESARO, where she led multiple biologic development programs. Dr. Laken also held strategic drug development leadership roles at Rhythm Pharmaceuticals, Pfizer, and Wyeth.
AI Analysis | Feedback
The key risks for Zenas BioPharma (ZBIO) are:
- Clinical Trial and Regulatory Approval Risk: Zenas BioPharma is a clinical-stage company with no products approved for commercial sale and no revenue generated from product sales. The company's entire business and future revenue generation depend on the successful completion of clinical trials for its lead product candidate, obexelimab, across its various indications (IgG4-RD, MS, SLE, wAIHA), and subsequently obtaining regulatory approvals from health authorities. Failure in any of these critical stages due to issues with efficacy, safety, or other regulatory hurdles would fundamentally undermine the company's prospects.
- Product Candidate Concentration Risk: Zenas BioPharma's strategy is heavily centered on developing obexelimab as its lead "I&I franchise" product candidate for multiple autoimmune diseases. While pursuing several indications, the company's pipeline is currently reliant on the success of this single bifunctional monoclonal antibody. Should obexelimab fail to demonstrate sufficient efficacy or an acceptable safety profile, or encounter unforeseen development or commercialization challenges, the company's entire business model would be severely impacted due to its lack of other late-stage diversified product candidates.
AI Analysis | Feedback
nullAI Analysis | Feedback
Zenas BioPharma (ZBIO) is developing obexelimab for several autoimmune diseases, with the following estimated addressable market sizes in the U.S.:| Product/Service | Addressable Market Size | Region |
|---|---|---|
| Obexelimab for Immunoglobulin G4-related disease (IgG4-RD) | Approximately 20,000 diagnosed patients | U.S. |
| Obexelimab for Multiple Sclerosis (MS) | Approximately 650,000 diagnosed patients | U.S. |
| Obexelimab for Systemic Lupus Erythematosus (SLE) | Approximately 172,000 diagnosed patients | U.S. |
| Obexelimab for Warm Autoimmune Hemolytic Anemia (wAIHA) | Approximately 40,000 diagnosed patients | U.S. |
| Aggregate Commercial Opportunity (Obexelimab across the four indications) | Approximately $50 billion | U.S. |
AI Analysis | Feedback
The primary drivers of future revenue growth for Zenas BioPharma (ZBIO) over the next 2-3 years are centered on the successful development and commercialization of its lead product candidate, obexelimab, across multiple autoimmune disease indications:
- Successful Clinical Development and Regulatory Approval of Obexelimab for IgG4-RD: Zenas BioPharma is currently conducting a registration-directed Phase 3 trial for obexelimab in immunoglobulin G4-related disease (IgG4-RD). Successful completion of this trial and subsequent regulatory approval would mark the company's first potential product launch and revenue generation.
- Commercial Launch and Market Penetration of Obexelimab for IgG4-RD: Following regulatory approval for IgG4-RD, the effective commercial launch and successful market penetration of obexelimab within this indication will directly drive initial revenue growth. The company estimates a diagnosed population of approximately 20,000 IgG4-RD patients in the United States, representing a significant commercial opportunity upon launch.
- Advancement and Expansion of Obexelimab into Additional Autoimmune Disease Indications: Zenas BioPharma is also developing obexelimab for multiple sclerosis (MS) and systemic lupus erythematosus (SLE) through Phase 2 trials, and for warm autoimmune hemolytic anemia (wAIHA) through an ongoing Phase 2/3 trial. Positive clinical trial outcomes and progression of obexelimab into later-stage development and eventual approval in these indications, which represent significantly larger patient populations (estimated at 650,000 for MS, 172,000 for SLE, and 40,000 for wAIHA in the U.S.), would substantially expand obexelimab's total addressable market and serve as major drivers for sustained future revenue growth.
AI Analysis | Feedback
Share Issuance
- Zenas BioPharma completed an initial public offering (IPO) in September 2024, raising approximately $258.7 million in gross proceeds, including the full exercise of the underwriters' option to purchase additional shares. Net proceeds from the IPO totaled $234.4 million through the sale of 13.23 million shares at $17 per share.
- In October 2025, the company secured a $120 million private placement by issuing approximately 6.3 million shares to institutional and accredited investors at $19.00 per share.
- Prior to its IPO, Zenas BioPharma raised a total of $318 million across three funding rounds, with its largest, a Series C round, occurring in May 2024 for $200.15 million.
Inbound Investments
- Zenas BioPharma entered into a revenue participation and funding agreement with Royalty Pharma, which will provide up to $300 million in consideration, including an upfront payment of $75 million.
- The company successfully completed a Series C funding round in May 2024, raising $200.15 million, co-led by SR One, New Enterprise Associates, Norwest Venture Partners, and Delos Capital Partners.
- A private placement completed in October 2025 brought in $120 million from institutional and accredited investors, as well as company directors and officers.
Outbound Investments
- Zenas BioPharma made a strategic investment through a license agreement with InnoCare, which included a $35.0 million upfront payment for exclusive development and manufacturing rights for product candidates, such as orelabrutinib. A $5.0 million deposit related to this upfront payment was recognized as acquired in-process research and development expenses in the quarter ended September 30, 2025.
Capital Expenditures
- Capital expenditures were reported as -$92,000 in the last 12 months, and $0.00 in the most recent quarter.
- The company anticipates that its cash, cash equivalents, and investments will cover its operating expenses and capital expenditure requirements into the fourth quarter of 2026.
- The primary focus of capital allocation is on supporting ongoing research and development activities and clinical trials for its lead product candidates, obexelimab and orelabrutinib.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Zenas BioPharma Stock Pre-Market (-4.4%): Shareholder Lawsuit Investigation Announced | 01/15/2026 | |
| Zenas BioPharma Stock Pre-Market (-4.0%) : Fallout From Phase 3 Data Disappointment | 01/06/2026 | |
| Zenas BioPharma Earnings Notes | 12/16/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to ZBIO.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 10312025 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | -38.2% | -38.2% | -51.4% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 206.94 |
| Mkt Cap | 146.2 |
| Rev LTM | 42,852 |
| Op Inc LTM | 12,080 |
| FCF LTM | 9,482 |
| FCF 3Y Avg | 5,418 |
| CFO LTM | 12,031 |
| CFO 3Y Avg | 10,753 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.5% |
| Rev Chg 3Y Avg | 4.4% |
| Rev Chg Q | 4.2% |
| QoQ Delta Rev Chg LTM | 0.9% |
| Op Inc Chg LTM | 31.3% |
| Op Inc Chg 3Y Avg | 8.8% |
| Op Mgn LTM | 27.4% |
| Op Mgn 3Y Avg | 23.4% |
| QoQ Delta Op Mgn LTM | -0.4% |
| CFO/Rev LTM | 26.8% |
| CFO/Rev 3Y Avg | 24.7% |
| FCF/Rev LTM | 20.6% |
| FCF/Rev 3Y Avg | 20.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 146.2 |
| P/S | 5.2 |
| P/Op Inc | 14.5 |
| P/EBIT | 15.0 |
| P/E | 21.7 |
| P/CFO | 13.7 |
| Total Yield | 5.6% |
| Dividend Yield | 1.5% |
| FCF Yield 3Y Avg | 5.2% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -2.8% |
| 3M Rtn | -5.2% |
| 6M Rtn | 13.1% |
| 12M Rtn | 35.9% |
| 3Y Rtn | 28.0% |
| 1M Excs Rtn | -13.6% |
| 3M Excs Rtn | -13.1% |
| 6M Excs Rtn | 8.1% |
| 12M Excs Rtn | 6.5% |
| 3Y Excs Rtn | -51.3% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Research and development of precision immunology-based therapies | 5 | 0 | |
| Total | 5 | 0 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Research and development of precision immunology-based therapies | -157 | ||
| Total | -157 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Research and development of precision immunology-based therapies | 68 | 75 | |
| Total | 68 | 75 |
Price Behavior
| Market Price | $19.27 | |
| Market Cap ($ Bil) | 1.0 | |
| First Trading Date | 09/13/2024 | |
| Distance from 52W High | -55.4% | |
| 50 Days | 200 Days | |
| DMA Price | $21.85 | $22.60 |
| DMA Trend | up | down |
| Distance from DMA | -11.8% | -14.8% |
| 3M | 1YR | |
| Volatility | 75.7% | 115.2% |
| Downside Capture | 0.95 | 0.95 |
| Upside Capture | 96.77 | 225.29 |
| Correlation (SPY) | 16.4% | 15.8% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.78 | 1.52 | 0.70 | 0.19 | 1.59 | 0.28 |
| Up Beta | -0.90 | -0.83 | -0.42 | -0.95 | 0.30 | -0.26 |
| Down Beta | -1.88 | 2.40 | 0.49 | 0.00 | 0.95 | 1.76 |
| Up Capture | 157% | 103% | 89% | -6% | 432% | 56% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 12 | 20 | 32 | 67 | 135 | 207 |
| Down Capture | 1312% | 323% | 160% | 101% | 169% | 100% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 10 | 23 | 32 | 58 | 116 | 198 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ZBIO | |
|---|---|---|---|---|
| ZBIO | 123.6% | 115.2% | 1.29 | - |
| Sector ETF (XLV) | 9.7% | 15.4% | 0.40 | 21.3% |
| Equity (SPY) | 29.6% | 12.5% | 1.86 | 15.5% |
| Gold (GLD) | 37.0% | 27.1% | 1.14 | 7.9% |
| Commodities (DBC) | 48.7% | 18.0% | 2.12 | -2.4% |
| Real Estate (VNQ) | 12.9% | 13.5% | 0.65 | 11.2% |
| Bitcoin (BTCUSD) | -16.3% | 42.1% | -0.31 | 14.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ZBIO | |
|---|---|---|---|---|
| ZBIO | 2.1% | 110.4% | 0.60 | - |
| Sector ETF (XLV) | 5.3% | 14.6% | 0.18 | 19.7% |
| Equity (SPY) | 12.8% | 17.1% | 0.59 | 20.3% |
| Gold (GLD) | 21.1% | 17.9% | 0.96 | 5.5% |
| Commodities (DBC) | 14.1% | 19.1% | 0.60 | 0.4% |
| Real Estate (VNQ) | 3.3% | 18.8% | 0.08 | 13.8% |
| Bitcoin (BTCUSD) | 7.0% | 56.0% | 0.34 | 15.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ZBIO | |
|---|---|---|---|---|
| ZBIO | 1.0% | 110.4% | 0.60 | - |
| Sector ETF (XLV) | 9.3% | 16.5% | 0.45 | 19.7% |
| Equity (SPY) | 15.0% | 17.9% | 0.72 | 20.3% |
| Gold (GLD) | 13.5% | 16.0% | 0.70 | 5.5% |
| Commodities (DBC) | 9.4% | 17.8% | 0.44 | 0.4% |
| Real Estate (VNQ) | 5.7% | 20.7% | 0.24 | 13.8% |
| Bitcoin (BTCUSD) | 68.2% | 66.9% | 1.07 | 15.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/16/2026 | -3.4% | -7.2% | -11.2% |
| 11/12/2025 | 1.7% | 2.9% | 15.3% |
| 8/12/2025 | 6.7% | 15.9% | 32.8% |
| 5/15/2025 | 12.2% | 26.0% | 19.0% |
| 2/5/2025 | 3.4% | -5.1% | -5.1% |
| 11/12/2024 | -3.1% | -29.1% | -56.9% |
| SUMMARY STATS | |||
| # Positive | 4 | 3 | 3 |
| # Negative | 2 | 3 | 3 |
| Median Positive | 5.0% | 15.9% | 19.0% |
| Median Negative | -3.2% | -7.2% | -11.2% |
| Max Positive | 12.2% | 26.0% | 32.8% |
| Max Negative | -3.4% | -29.1% | -56.9% |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Moulder, Leon O JR | Chief Executive Officer | See Footnote | Buy | 4292026 | 17.62 | 35,000 | 616,700 | 31,470,007 | Form |
| 2 | Moulder, Leon O JR | Chief Executive Officer | See Footnote | Buy | 4292026 | 18.02 | 25,000 | 450,500 | 31,553,723 | Form |
| 3 | Lu, Hongbo | See footnote | Buy | 4022026 | 18.63 | 3,768 | 70,198 | 7,950,092 | Form | |
| 4 | Moulder, Leon O JR | Chief Executive Officer | See Footnote | Buy | 3312026 | 19.31 | 34,000 | 656,540 | 33,329,813 | Form |
| 5 | Lu, Hongbo | See footnote | Buy | 3312026 | 20.00 | 75,000 | 1,500,000 | 8,459,360 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.